Clarify the Role of Opzelura for Eczema

December 2021

Opzelura (ruxolitinib) 1.5% cream will be the first topical Janus kinase (JAK) inhibitor approved for mild to moderate eczema.

It suppresses cytokines to improve itching and inflammation.

Opzelura is thought to be safer than oral JAK inhibitors (Xeljanz, etc)...since it seems to have less than 10% systemic absorption.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote